PEPG
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- PepGen advanced PGN-EDODM1 to the highest dose cohort in the Phase 2 FREEDOM2-DM1 study following DSMB reviewAug 6, 2026
- PepGen reported positive topline results from the lowest dose cohort in the Phase 2 FREEDOM2 studyMar 31, 2026
- PepGen announces issuance of a U.S. patent for its proprietary PGN‑EDODM1 moleculeNov 12, 2025
- PepGen focuses on advancing its promising DM1 program after 10 mg/kg PGN-EDO51 updateMay 29, 2025